Adagio Medical Holdings, Inc.

For the period ended Dec 31, 2024. Filed Mar 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 27, 2025

ADGM$1.84-4.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

(in thousands)


	Years Ended December 31
· · 2024 · · 2023
· · Successor · · · Predecessor · · Predecessor
· · July 31 to December 31 · · · January 1 to July 30 · · January 1 to December 31
Cash flows from operating activities: · · · · · · · · ·
Net loss		$(53,763)	$(21,278)	$(36,590)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		740	646	532
Non-cash operating lease expense		56	98	159
Stock-based compensation		—	642	442
Provision for inventory impairment		(4)	15	25
Amortization of term loan discount		—	10	16
Loss on disposal of property and equipment		—	62	3
Impairment - Goodwill		30,324	—	—
Impairment - Intangible assets, net		18,878	—	—
Change in fair value of convertible notes payable		(929)	(2,059)	6,930
Change in fair value of warrant liabilities		(6,576)	(191)	42
Net change in operating assets and liabilities:
Accounts receivable, net		67	(32)	(70)
Inventory, net		1,399	(773)	(2,976)
Prepaid expenses and other current assets		(886)	(95)	410
Accounts payable		(1,933)	(2,628)	2,821
Accrued liabilities		127	511	886
Accrued transaction costs		3	7,446	444
Other accrued liabilities		1,001	1,734	1,435
Operating lease liabilities		(56)	(98)	(161)
Other long-term liabilities		—	—	—
Deferred taxes		(1,917)	—	—
Net cash used in operating activities		(13,469)	(15,990)	(25,652)
Cash flows from investing activities:
Purchases of property and equipment		(1,280)	(368)	(333)
Purchases of software		—	—	(7)
Net cash used in investing activities:		(1,280)	(368)	(340)
Cash flows from financing activities:
Proceeds from exercise of common stock options		—	—	18
Proceeds from issuance of convertible notes payable		—	16,500	20,000
Proceeds from term loan		—	—	3,000
Repayment of non-convertible term loan		—	(867)	(1,143)
Net cash provided by financing activities		—	15,633	21,875
Effect of foreign currency translation on cash and cash equivalents		181	24	(47)
Net change in cash and cash equivalents		(14,568)	(701)	(4,164)
Cash and cash equivalents, at beginning of period		35,154	1,383	5,547
Cash and cash equivalents, at end of period		$20,586	$682	$1,383

Supplemental disclosure of cash flow information:
Cash paid for interest		$—	$85	$208
Supplemental disclosure of noncash investing and financing activities:
Right-of-use assets obtained in exchange for lease liabilities		$—	$(216)	$—
Lease liabilities recorded for operating lease right-of-use assets		$—	$216	$—
Amount of term loan proceeds allocated to warrant liabilities		$—	$—	$36
Exchange preferred stock for pre-funded warrants		$—	$4,332	$—

Adagio Medical Holding, Inc.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.